+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07215949

Evaluating Daily Subcutaneous Zilucoplan for Severe Exacerbations in Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis Requiring Hospitalization

Led by Miriam Freimer · Updated on 2026-08-28

15

Participants Needed

3

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the use of subcutaneous zilucoplan injections in adults with acetylcholine receptor antibody positive generalized myasthenia gravis gMG who experience severe exacerbations requiring hospitalization. This phase 3b open-label trial aims to assess if zilucoplan can quickly improve severe symptoms such as respiratory or bulbar dysfunction. The study also explores whether this treatment could offer a less invasive alternative to current therapies like plasma exchange or intravenous immunoglobulin IVIG. Participants will receive daily subcutaneous injections of zilucoplan for 12 weeks, with dosing based on body weight. Treatment begins in the hospital and continues after discharge as an outpatient. Before starting zilucoplan, patients will be vaccinated against meningitis and take antibiotics until vaccination is complete. Patients may also choose standard care options such as plasma exchange or IVIG instead of the study treatment. During the approximately 18-week participation, researchers will monitor medical history, physical exams, vital signs, blood tests, and myasthenia gravis assessments including the Quantitative Myasthenia Gravis QMG score and Myasthenia Gravis Activities of Daily Living MG-ADL scale. Quality of life will be evaluated using the MG Quality of Life 15-item Revised MGQoL15r questionnaire. Ongoing review of medications and side effects will occur. The primary outcome focuses on changes in MG-ADL scores from baseline to Week 2, with additional assessments through Week 12.

CONDITIONS

Brief Title

Zilucoplan for Severe gMG Exacerbations

Research Team

J

Julie Agriesti, MACPR, CCRC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here